Compare Medpace Holdings Inc (MEDP) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Toyota Motor Corp — how do they compare? Medpace Holdings Inc trades at $611.72 (market cap $16.82B), while Toyota Motor Corp trades at $184.76 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 12.9× Medpace Holdings Inc's market cap, and Toyota Motor Corp pays a 3.37% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Toyota Motor Corp for 116 Days on average.
| MEDP | TM | |
|---|---|---|
Market Cap | $16.82B | $217.38B |
Volume | 223,093 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $248.29 |
52-Week Low | $393.42 | $166.50 |
Typical Hold Time | 14 Days | 116 Days |
Enterprise Value | $16.44B | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Toyota Motor trades at $185.17, up 1.24% with a bearish technical signal despite strong fundamentals. The stock shows attractive valuation metrics with a P/E of 8.38 and P/S of 0.73, while delivering consistent earnings beats in recent quarters. Recent news highlights strong U.S. sales performance and electrification progress, though technical indicators show selling pressure with key support at $184.
Toyota presents a value opportunity with solid profitability and clean balance sheet, though near-term headwinds include China sales weakness and production disruptions. Analyst consensus leans cautious with 62.5% hold ratings, reflecting concerns about profit margin compression despite the company's market leadership and electrification investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
